AI identifies rectal cancer patients who benefit from irinotecan combo therapy

Advanced rectal cancer patients with high tumor cell density can now avoid unnecessary debilitating side effects from intensive treatments if identified as non-responders through AI analysis.

At University College London, researchers have turned a failed clinical trial into a quiet breakthrough: an artificial intelligence trained to read the density of cancer cells in tumor biopsies can now distinguish, before treatment begins, which rectal cancer patients will genuinely benefit from an intensive drug combination—and which will only suffer from it. The ARISTOTLE trial once seemed to close the door on irinotecan as a broad therapy; the AI has reopened it, more narrowly and more wisely. In a disease that ranks among the UK's deadliest, the ability to match treatment to tumor biology

AI identifies rectal cancer patients who benefit from irinotecan combo therapy

Cobertura Relacionada

Receba o Register no seu e-mail